PYC Therapeutics (PYC.AX) Stock Price
PYC Therapeutics Price
Over the last 18 years PYC Therapeutics grew revenue by 28.0% annually, reaching 23.49 M AUD. For PYC Therapeutics, the net margin of -214.1% is up versus -577.9% a few years ago. The consensus 12-month price target for PYC Therapeutics is 3.96 AUD, about 61.5% above where the stock trades today. Of 9 analysts, 8 rate the stock a buy — an overall Buy consensus.
PYC Therapeutics stock price
PYC Therapeutics business model & stock analysis
Frequently asked questions about PYC Therapeutics
The business model of PYC Therapeutics Ltd is focused on the discovery and development of novel RNA-targeted therapies to address genetic diseases caused by RNA gain-of-function. By utilizing their proprietary platform called RNA PROTEIN BINDING MOTIFS (RBMs), PYC Therapeutics aims to unlock the potential of RNA therapeutics and provide innovative solutions for patients with unmet medical needs. With their specialized expertise in RNA biology and drug discovery, PYC Therapeutics is dedicated to advancing their pipeline of RNA-targeted therapies and making a meaningful impact in the field of precision medicine.
PYC Therapeutics Ltd is primarily active in the pharmaceutical and biotechnology industries.
The main competitors of PYC Therapeutics Ltd in the market are other companies involved in the field of gene therapy and genetic diseases, such as Sarepta Therapeutics, Solid Biosciences, and Spark Therapeutics.
PYC Therapeutics Ltd is an innovative biotechnology company based in Australia. Established in 1996, the company has a rich history in developing novel therapeutics for genetic diseases. With a strong focus on precision medicine, PYC Therapeutics utilizes its proprietary platform, known as aRNA, to develop RNA-based therapies that target specific genes and restore their normal function. The company has gained recognition for its groundbreaking research and collaborations with leading academic and healthcare institutions. As a result, PYC Therapeutics is well-poised to address the unmet medical needs of patients with genetic disorders and drive advancements in the field of precision medicine.
PYC Therapeutics Ltd has achieved several significant milestones. The company successfully completed its initial public offering in August 2020, raising substantial funds to support its research and development efforts. Additionally, PYC Therapeutics has made remarkable progress in advancing its proprietary RNA splicing platform, which holds tremendous potential in treating genetic diseases. The company has also secured strategic partnerships and collaborations with renowned academic institutions and pharmaceutical companies, further validating the potential of its innovative technologies. PYC Therapeutics continues to actively pursue groundbreaking research and development activities, solidifying its position as a leading player in the field of genetic medicine.
PYC Therapeutics Ltd is primarily present in Australia.
PYC Therapeutics Ltd is a biotechnology company that focuses on developing transformative RNA therapeutics to treat a range of genetic diseases. The company is committed to delivering innovative solutions aimed at improving patients' lives and addressing unmet medical needs. PYC Therapeutics is guided by a strong corporate philosophy centered around scientific excellence, collaboration, and integrity. By leveraging cutting-edge RNA technologies and a deep understanding of disease biology, PYC Therapeutics aims to advance groundbreaking therapies and make a significant impact in the field of genetic medicine.
Analysts currently set an average price target of 3.63 AUD for the PYC Therapeutics stock (median: 3.96 AUD), implying +48.0 % versus the latest price. The consensus is based on 9 analyst ratings.
9 analysts currently rate the PYC Therapeutics stock: 8 recommend buying, 1 holding and 0 selling.
Converted at the current exchange rate, the PYC Therapeutics share trades at 1.53 EUR (2.45 AUD).
The PYC Therapeutics share (PYC.AX) is listed on 2 stock exchanges, including: ASX (PYC.AX), Frankfurt (PH7.F).
PYC Therapeutics Ltd is a pharmaceutical company specializing in the development and commercialization of therapeutic solutions for rare genetic diseases. The company is headquartered in Australia and has branches in the USA and UK. PYC Therapeutics focuses on diseases caused by mutations in the RNA splicing process. The business model of PYC Therapeutics is based on the development of new generations of RNA splicing modulators that enable correct RNA splicing. RNA splicing modulation aims to develop novel therapeutic approaches to combat previously incurable rare diseases. The company uses newly gained molecular insights to develop targeted therapeutic approaches. An important division of PYC Therapeutics is nucleic acid-based therapeutics targeting mRNA modulation. The products in this division aim to correct "mis-spliced" mRNA and allow for the production of healthy proteins. One outstanding product of PYC Therapeutics is the RNA splicing modulation therapy PYC46. This therapy aims to produce a protein that prevents the entry of viruses into cells by correcting mis-spliced RNA. What makes PYC46 special is that this therapy can have broad applications in fighting various viruses. The company has also formed a partnership with the American company Ultragenyx Pharmaceutical Inc. to jointly advance the development of RNA splicing modulators. Ultragenyx Pharmaceutical Inc. is a renowned biotech company specializing in rare diseases. The partnership allows both companies to leverage synergies to drive the development of new and effective therapeutics. PYC Therapeutics aims to develop a variety of new therapeutic approaches for the treatment of rare genetic diseases and make them accessible to the millions of people affected by these rare diseases. The company relies on close collaboration with academic institutions and research facilities in the industry to advance its research and development initiatives. Overall, PYC Therapeutics places great importance on well-founded and sustainable research and development. Only on this basis can the company develop innovative solutions and products to provide high benefits to patients worldwide.
The revenue cannot currently be calculated for PYC Therapeutics.
The profit of PYC Therapeutics is -43.34 M AUD. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of PYC Therapeutics is currently -41.41. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the PYC Therapeutics stock.
The P/S cannot be calculated for PYC Therapeutics currently.
The Eulerpool Quality Score for PYC Therapeutics is 2/10.
The ISIN of PYC Therapeutics is AU000000PYC7. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of PYC Therapeutics is A0D8ZY. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of PYC Therapeutics is PYC.AX. The ticker symbol is used to trade PYC Therapeutics shares on the stock exchange.
PYC Therapeutics stock
PYC Therapeutics Peer Group
PYC Therapeutics Ticker
PYC Therapeutics FIGI
All fundamentals and in-depth analysis of PYC Therapeutics
Our stock analysis for PYC Therapeutics stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of PYC Therapeutics. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.